Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - zolmitriptan - film coated tablet - 2.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - zolmitriptan - orodispersible tablet - 2.5 milligram

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin aspart - diabetes mellitus - drugs used in diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - cabazitaxel acetone solvate; cabazitaxel -

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - peppermint oil - gastro-resistant capsule, soft - 0.2 millilitre(s) - other drugs for functional gastrointestinal disorders

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml; lixisenatide 0.1 mg/ml - solution for injection - 0.05mg/ml + 0.1mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - insulin glargine - injection, solution - 100 iu/ml - insulin glargine 100 iu/ml

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - insulin glulisine - injection, solution - 3.49 mg - insulin glulisine 3.49 mg